계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
ViewRay
company
Funding Rounds
Number of Funding Rounds
Total Funding Amount
22
$877.79M 0
ViewRay has raised a total of
$877.79M 0 in funding over 2 rounds. Their latest funding was raised on
Nov 14, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 14, 2022 | Post-IPO Debt | $125M | 2 | MidCap Financial , Silicon Valley Bank | — | Detail |
| Nov 19, 2021 | Post-IPO Equity | $80.50M | — | — | — | Detail |
| Dec 6, 2019 | Post-IPO Equity | $36M | 1 | Elekta | — | Detail |
| Jan 1, 2019 | Debt Financing | $56M | 1 | — | — | Detail |
| Aug 20, 2018 | Post-IPO Equity | $172.50M | — | — | — | Detail |
| Feb 26, 2018 | Post-IPO Equity | $59M | — | — | — | Detail |
| Oct 25, 2017 | Post-IPO Equity | $50M | — | — | — | Detail |
| Jan 18, 2017 | Post-IPO Equity | $26.10M | 4 | Puissance Capital | — | Detail |
| Aug 22, 2016 | Post-IPO Equity | $14M | 3 | Kearny Venture Partners , OrbiMed , Xeraya Capital | — | Detail |
| Aug 28, 2015 | Post-IPO Equity | $2.71M | — | — | — | Detail |
| Aug 18, 2015 | IPO | — | — | — | — | Detail |
| Jul 24, 2015 | Post-IPO Equity | $26.70M | 6 | — | — | Detail |
| Jun 30, 2015 | Post-IPO Debt | $50M | 1 | — | — | Detail |
| Mar 4, 2015 | Series Unknown | $15M | — | — | — | Detail |
| Jan 9, 2015 | Series C | $16.27M | — | — | — | Detail |
| Dec 17, 2013 | Series Unknown | $30M | 5 | — | — | Detail |
| May 21, 2013 | Series Unknown | $15M | 5 | — | — | Detail |
| Mar 13, 2012 | Series C | $45M | 5 | — | — | Detail |
| Sep 2, 2011 | Debt Financing | $10M | 5 | — | — | Detail |
| Aug 25, 2010 | Series C | $20M | 5 | Next47 | — | Detail |
| Jan 23, 2008 | Series B | $25M | 5 | F-Prime Capital , OrbiMed | — | Detail |
| Aug 8, 2007 | Series A | $3M | — | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
